Unknown

Dataset Information

0

Ibrutinib enhances chimeric antigen receptor T-cell engraftment and efficacy in leukemia.


ABSTRACT: Anti-CD19 chimeric antigen receptor (CAR) T-cell therapy is highly promising but requires robust T-cell expansion and engraftment. A T-cell defect in chronic lymphocytic leukemia (CLL) due to disease and/or therapy impairs ex vivo expansion and response to CAR T cells. To evaluate the effect of ibrutinib treatment on the T-cell compartment in CLL as it relates to CAR T-cell generation, we examined the phenotype and function of T cells in a cohort of CLL patients during their course of treatment with ibrutinib. We found that ?5 cycles of ibrutinib therapy improved the expansion of CD19-directed CAR T cells (CTL019), in association with decreased expression of the immunosuppressive molecule programmed cell death 1 on T cells and of CD200 on B-CLL cells. In support of these findings, we observed that 3 CLL patients who had been treated with ibrutinib for ?1 year at the time of T-cell collection had improved ex vivo and in vivo CTL019 expansion, which correlated positively together and with clinical response. Lastly, we show that ibrutinib exposure does not impair CAR T-cell function in vitro but does improve CAR T-cell engraftment, tumor clearance, and survival in human xenograft models of resistant acute lymphocytic leukemia and CLL when administered concurrently. Our collective findings indicate that ibrutinib enhances CAR T-cell function and suggest that clinical trials with combination therapy are warranted. Our studies demonstrate that improved T-cell function may also contribute to the efficacy of ibrutinib in CLL. These trials were registered at www.clinicaltrials.gov as #NCT01747486, #NCT01105247, and #NCT01217749.

SUBMITTER: Fraietta JA 

PROVIDER: S-EPMC4778162 | biostudies-literature | 2016 Mar

REPOSITORIES: biostudies-literature

altmetric image

Publications


Anti-CD19 chimeric antigen receptor (CAR) T-cell therapy is highly promising but requires robust T-cell expansion and engraftment. A T-cell defect in chronic lymphocytic leukemia (CLL) due to disease and/or therapy impairs ex vivo expansion and response to CAR T cells. To evaluate the effect of ibrutinib treatment on the T-cell compartment in CLL as it relates to CAR T-cell generation, we examined the phenotype and function of T cells in a cohort of CLL patients during their course of treatment  ...[more]

Similar Datasets

| S-EPMC5330718 | biostudies-literature
| S-EPMC8293573 | biostudies-literature
| S-EPMC7461863 | biostudies-literature
| S-EPMC7388644 | biostudies-literature
| S-EPMC7269829 | biostudies-literature
| S-EPMC6247712 | biostudies-literature
2021-06-03 | GSE151774 | GEO
| S-EPMC6406805 | biostudies-literature
| S-EPMC8905689 | biostudies-literature
| S-EPMC5590803 | biostudies-literature